Peptic ulcer (PU) bleeding is the main cause of non-variceal gastrointestinal bleeding. Negative outcomes include re-bleeding and death, and many of the deaths are associated with decompensation of coexisting medical conditions precipitated by acute bleeding event. Accurate analysis of risk for clinical features can help physician to decide treatment modality. Endoscopy can detect bleeding stigmata and perform therapeutic hemostasis. Proton pump inhibitor (PPI) compared with placebo or H2RA reduces mortality following PU bleeding among patients with high-risk endoscopic findings, and reduces re-bleeding rates and surgical intervention. PPI treatment initiated prior to endoscopy in upper gastrointestinal (UGI) bleeding significantly reduces the proportion of patients with stigmata of recent hemorrhage (SRH) at index endoscopy but does not reduce mortality, re-bleeding or the need for surgery. The strategy of giving oral PPI before and after endoscopy, with endoscopic hemostasis for those with major SRH, is likely to be the most cost-effective. The treatment of H. pylori infection was found to be more effective than anti-secretory therapy in preventing recurrent bleeding from PU. H. pylori eradication alone and eradication followed by misoprostol (with switch to PPI, if misoprostol is not tolerated) are the two most cost-effective strategies to prevent ulcer bleeding among H. pylori-infected NSAID users, although the data cannot exclude PPIs also being cost-effective treatment. This review focuses specifically on the current treatment of patients with acute bleeding from a peptic ulcer. (Korean J Gastroenterol 2009;54:298-308)
, hypotension (systolic blood pressure, ＜100 mmHg), or postural changes (increase in pulse of ＞20 beats per minute or a drop in systolic blood pressure of ＞20 mm Hg on standing), or hemodynamic stability within 3 hours after initial evaluation 3. Absence of a severe coexisting illness (e.g., heart failure, chronic obstructive pulmonary disease, hepatic cirrhosis, hematologic cancer, chronic renal failure, and cerebrovascular accident) 4. A hemoglobin level of more than 8 to 10 g per deciliter after adequate intravascular volume expansion and no need for blood transfusion 5. Normal coagulation studies 6. Onset of bleeding outside the hospital 7. Presence of a clean-base ulcer or no obvious endoscopic finding on early endoscopcy (performed within 24 hours after presentation) 8. Adequate social support at home with the ability to return promptly to a hospital 시행결과에 따라 퇴원하여 귀가할 수 있다. [35] [36] [37] [38] [39] 저위험군 환 자 치료를 위한 선택적인 보존 치료 범주의 요약은 
